,i #aahth ,,congress #ast ,session ,h4 ,r4 #dhdf ,,in ,,the ,,house ,,of ,,representatives ,july #be1 #bjbc,mr4 ,arrington introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on ,ways and ,means1 and ,education and the ,workforce1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend the ,internal ,revenue ,code of #aihf1 title ,,xxvii of the ,public ,health ,service ,act1 and the ,employee ,retirement ,income ,security ,act of #aigd to provide for oversight of pharmacy benefit manager services4 #a4 ,short title ,this ,act may be cited as the ,better ,deals and ,lower ,prices ,act4 #b4 ,oversight of pharmacy benefits manager services 7a7 ,,irc 7#a7 ,in general ,subchapter ,b of chapter #ajj of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following3 #ihbf4 ,oversight of pharmacy benefits manager services 7a7 ,in general ,for plan years beginning on or after the date that is #c years after the date of enactment of this section1 a group health plan1 or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan1 shall not enter into a contract with a drug manufacturer1 distributor1 wholesaler1 subcontractor1 rebate aggregator1 or any associated third party that limits the disclosure of information to plan sponsors in such a manner that prevents the plan1 or an entity or subsidiary providing pharmacy benefits management services on behalf of a plan1 from making the report described in subsection 7b74 7b7 ,annual report 7#a7 ,in general ,with respect to plan years beginning on or after the date that is #c years after the date of enactment of this section1 for each such plan year1 a group health plan1 or an entity providing pharmacy benefits management services on behalf of such a plan1 shall submit to the plan sponsor 7as defined in section #c7af77;,b7 of the ,employee ,retirement ,income ,security ,act of #aigd7 of such plan a report in a machine-readable format4 ,each such report shall include1 with respect to such plan provided for such plan year-- 7,a7 to the extent feasible1 information collected from drug manufacturers 7or an entity administering copay assistance on behalf of such manufacturers7 by such plan on the total amount of copayment assistance dollars paid1 or copayment cards applied1 that were funded by the drug manufacturer with respect to the participants and beneficiaries in such plan2 7,b7 a list of each drug covered by such plan that was dispensed during the plan year1 including1 with respect to each such drug during such plan year-- 7i7 the brand name1 chemical entity1 and ,national ,drug ,code2 7ii7 the number of participants and beneficiaries for whom the drug was dispensed during the plan year1 the total number of prescription claims for the drug 7including original prescriptions and refills71 and the total number of dosage units of the drug dispensed across the plan year1 disaggregated by dispensing channel 7such as retail1 mail order1 or specialty pharmacy72 7iii7 the wholesale acquisition cost1 listed as cost per days supply and cost per pill1 or in the case of a drug in another form1 per dosage unit2 7iv7 the total out-of-pocket spending by participants and beneficiaries on such drug1 including participant and beneficiary spending through copayments1 coinsurance1 and deductibles2 7v7 for any drug for which gross spending of the group health plan exceeded #aj1jjj during the plan year-- 7,i7 a list of all other drugs in the same therapeutic category or class1 including brand name drugs and biological products and generic drugs or biosimilar biological products that are in the same therapeutic category or class as such drug2 and 7,,ii7 the rationale for the formulary placement of such drug in that therapeutic category or class1 if applicable2 7vi7 the amount received1 or expected to be received1 from drug manufacturers in rebates1 fees1 alternative discounts1 or other remuneration for claims incurred for such drug during the plan year2 7vii7 the total net spending1 after deducting rebates1 price concessions1 alternative discounts or other remuneration from drug manufacturers1 by the health plan on such drug2 and 7viii7 the net price per course of treatment or single fill1 such as a #cj-;day supply or #ij-;day supply1 incurred by the health plan and its participants and beneficiaries after manufacturer rebates1 fees1 and other remuneration for such drug dispensed during the plan year2 7,c7 a list of each therapeutic category or class of drugs that were dispensed under the health plan during the plan year1 and1 with respect to each such therapeutic category or class of drugs1 during the plan year-- 7i7 total gross spending by the plan1 before manufacturer rebates1 fees1 or other manufacturer remuneration2 7ii7 the number of participants and beneficiaries who were dispensed a drug covered by such plan in that category or class1 broken down by each such drug 7identified by ,national ,drug ,code72 7iii7 if applicable to that category or class1 a description of the formulary tiers and utilization management 7such as prior authorization or step therapy7 employed for drugs in that category or class2 and 7iv7 the total out-of-pocket spending by participants and beneficiaries1 including participant and beneficiary spending through copayments1 coinsurance1 and deductibles2 7,d7 total gross spending on prescription drugs by the plan during the plan year1 before rebates and other manufacturer fees or remuneration2 7,e7 total amount received1 or expected to be received1 by the health plan in drug manufacturer rebates1 fees1 alternative discounts1 and all other remuneration received from the manufacturer or any third party1 other than the plan sponsor1 related to utilization of drug or drug spending under that health plan during the plan year2 7,f7 the total net spending on prescription drugs by the health plan during the plan year2 and 7,g7 amounts paid directly or indirectly in rebates1 fees1 or any other type of remuneration to brokers1 consultants1 advisors1 or any other individual or firm for the referral of the group health plan's business to the pharmacy benefits manager4 7#b7 ,privacy requirements ,entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph 7#a7 in a manner consistent with the privacy1 security1 and breach notification regulations promulgated under section #bfd7;c7 of the ,health ,insurance ,portability and ,accountability ,act of #aiif1 and shall restrict the use and disclosure of such information according to such privacy regulations4 7#c7 ,disclosure and redisclosure 7,a7 ,limitation to business associates ,a group health plan receiving a report under paragraph 7#a7 may disclose such information only to business associates of such plan as defined in section #afj4ajc of title #de1 ,code of ,federal ,regulations 7or successor regulations74 7,b7 ,clarification regarding public disclosure of information ,nothing in this section prevents an entity providing pharmacy benefits management services on behalf of a group health plan from placing reasonable restrictions on the public disclosure of the information contained in a report described in paragraph 7#a71 except that such entity may not restrict disclosure of such report to the ,department of ,health and ,human ,services1 the ,department of ,labor1 the ,department of the ,treasury1 the ,comptroller ,general of the ,united ,states1 or applicable ,state agencies4 7,c7 ,limited form of report ,the ,secretary shall define through rulemaking a limited form of the report under paragraph 7#a7 required of plan sponsors who are drug manufacturers1 drug wholesalers1 or other direct participants in the drug supply chain1 in order to prevent anti-competitive behavior4 7#d7 ,report to ,,gao ,a group health plan1 or an entity providing pharmacy benefits management services on behalf of a group health plan1 shall submit to the ,comptroller ,general of the ,united ,states each of the first #d reports submitted to a plan sponsor under paragraph 7#a7 with respect to such plan1 and other such reports as requested1 in accordance with the privacy requirements under paragraph 7#b71 the disclosure and redisclosure standards under paragraph 7#c71 the standards specified pursuant to paragraph 7#e71 and such other information that the ,comptroller ,general determines necessary to carry out the study under section #b7;d7 of the ,better ,deals and ,lower ,prices ,act4 7#e7 ,standard format ,not later than #ah months after the date of enactment of this section1 the ,secretary shall specify through rulemaking standards for entities required to submit reports under paragraph 7#d7 to submit such reports in a standard format4 7c7 ,rule of construction ,nothing in this section shall be construed to permit a group health plan or other entity to restrict disclosure to1 or otherwise limit the access of1 the ,secretary of the ,treasury to a report described in subsection 7b77#a7 or information related to compliance with subsection 7a7 or 7b7 by such plan or other entity subject to such subsections4 7d7 ,definition ,in this section1 the term wholesale acquisition cost has the meaning given such term in section #ahdg;,a7c77#f77;,b7 of the ,social ,security ,act4 4 7#b7 ,clerical amendment ,the table of sections for subchapter ,b of chapter #ajj of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following new item3 ,sec4 #ihbf4 ,oversight of pharmacy benefits manager services4 4 7b7 ,,phsa ,title ,,xxvii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg et seq47 is amended-- 7#a7 in part ,d 7#db ,u4,s4,c4 #cjj;gg-#aaa et seq471 by adding at the end the following new section3 #bgii;,a-#aa4 ,oversight of pharmacy benefits manager services 7a7 ,in general ,for plan years beginning on or after the date that is #c years after the date of enactment of this section1 a group health plan or health insurance issuer offering group health insurance coverage1 or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan or issuer1 shall not enter into a contract with a drug manufacturer1 distributor1 wholesaler1 subcontractor1 rebate aggregator1 or any associated third party that limits the disclosure of information to plan sponsors in such a manner that prevents the plan or issuer1 or an entity or subsidiary providing pharmacy benefits management services on behalf of a plan or issuer1 from making the report described in subsection 7b74 7b7 ,annual report 7#a7 ,in general ,with respect to plan years beginning on or after the date that is #c years after the date of enactment of this section1 for each such plan year1 a group health plan or health insurance issuer offering group health insurance coverage1 or an entity providing pharmacy benefits management services on behalf of such a plan or an issuer1 shall submit to the plan sponsor 7as defined in section #c7af77;,b7 of the ,employee ,retirement ,income ,security ,act of #aigd7 of such plan or coverage a report in a machine-readable format4 ,each such report shall include1 with respect to such plan or coverage provided for such plan year-- 7,a7 to the extent feasible1 information collected from drug manufacturers 7or an entity administering copay assistance on behalf of such manufacturers7 by such plan or issuer on the total amount of copayment assistance dollars paid1 or copayment cards applied1 that were funded by the drug manufacturer with respect to the participants1 beneficiaries1 and enrollees in such plan or coverage2 7,b7 a list of each drug covered by such plan or coverage that was dispensed during the plan year1 including1 with respect to each such drug during such plan year-- 7i7 the brand name1 chemical entity1 and ,national ,drug ,code2 7ii7 the number of participants1 beneficiaries1 and enrollees for whom the drug was dispensed during the plan year1 the total number of prescription claims for the drug 7including original prescriptions and refills71 and the total number of dosage units of the drug dispensed across the plan year1 disaggregated by dispensing channel 7such as retail1 mail order1 or specialty pharmacy72 7iii7 the wholesale acquisition cost1 listed as cost per days supply and cost per pill1 or in the case of a drug in another form1 per dosage unit2 7iv7 the total out-of-pocket spending by participants1 beneficiaries1 and enrollees on such drug1 including participant1 beneficiary1 and enrollee spending through copayments1 coinsurance1 and deductibles2 7v7 for any drug for which gross spending of the group health plan or health insurance coverage exceeded #aj1jjj during the plan year-- 7,i7 a list of all other drugs in the same therapeutic category or class1 including brand name drugs and biological products and generic drugs or biosimilar biological products that are in the same therapeutic category or class as such drug2 and 7,,ii7 the rationale for the formulary placement of such drug in that therapeutic category or class1 if applicable2 7vi7 the amount received1 or expected to be received1 from drug manufacturers in rebates1 fees1 alternative discounts1 or other remuneration for claims incurred for such drug during the plan year2 7vii7 the total net spending1 after deducting rebates1 price concessions1 alternative discounts or other remuneration from drug manufacturers1 by the health plan or health insurance coverage on such drug2 and 7viii7 the net price per course of treatment or single fill1 such as a #cj-;day supply or #ij-;day supply1 incurred by the health plan or health insurance coverage and its participants1 beneficiaries1 and enrollees1 after manufacturer rebates1 fees1 and other remuneration for such drug dispensed during the plan year2 7,c7 a list of each therapeutic category or class of drugs that were dispensed under the health plan or health insurance coverage during the plan year1 and1 with respect to each such therapeutic category or class of drugs1 during the plan year-- 7i7 total gross spending by the plan or coverage1 before manufacturer rebates1 fees1 or other manufacturer remuneration2 7ii7 the number of participants1 beneficiaries1 and enrollees who were dispensed a drug covered by such plan or coverage in that category or class1 broken down by each such drug 7identified by ,national ,drug ,code72 7iii7 if applicable to that category or class1 a description of the formulary tiers and utilization management 7such as prior authorization or step therapy7 employed for drugs in that category or class2 and 7iv7 the total out-of-pocket spending by participants1 beneficiaries1 and enrollees1 including participant1 beneficiary1 and enrollee spending through copayments1 coinsurance1 and deductibles2 7,d7 total gross spending on prescription drugs by the plan or coverage during the plan year1 before rebates and other manufacturer fees or remuneration2 7,e7 total amount received1 or expected to be received1 by the health plan or health insurance coverage in drug manufacturer rebates1 fees1 alternative discounts1 and all other remuneration received from the manufacturer or any third party1 other than the plan sponsor1 related to utilization of drug or drug spending under that health plan or health insurance coverage during the plan year2 7,f7 the total net spending on prescription drugs by the health plan or health insurance coverage during the plan year2 and 7,g7 amounts paid directly or indirectly in rebates1 fees1 or any other type of remuneration to brokers1 consultants1 advisors1 or any other individual or firm for the referral of the group health plan's or health insurance issuer's business to the pharmacy benefits manager4 7#b7 ,privacy requirements ,health insurance issuers offering group health insurance coverage and entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph 7#a7 in a manner consistent with the privacy1 security1 and breach notification regulations promulgated under section #bfd7;c7 of the ,health ,insurance ,portability and ,accountability ,act of #aiif1 and shall restrict the use and disclosure of such information according to such privacy regulations4 7#c7 ,disclosure and redisclosure 7,a7 ,limitation to business associates ,a group health plan receiving a report under paragraph 7#a7 may disclose such information only to business associates of such plan as defined in section #afj4ajc of title #de1 ,code of ,federal ,regulations 7or successor regulations74 7,b7 ,clarification regarding public disclosure of information ,nothing in this section prevents a health insurance issuer offering group health insurance coverage or an entity providing pharmacy benefits management services on behalf of a group health plan from placing reasonable restrictions on the public disclosure of the information contained in a report described in paragraph 7#a71 except that such issuer or entity may not restrict disclosure of such report to the ,department of ,health and ,human ,services1 the ,department of ,labor1 the ,department of the ,treasury1 the ,comptroller ,general of the ,united ,states1 or applicable ,state agencies4 7,c7 ,limited form of report ,the ,secretary shall define through rulemaking a limited form of the report under paragraph 7#a7 required of plan sponsors who are drug manufacturers1 drug wholesalers1 or other direct participants in the drug supply chain1 in order to prevent anti-competitive behavior4 7#d7 ,report to ,,gao ,a group health plan or health insurance issuer offering group health insurance coverage1 or an entity providing pharmacy benefits management services on behalf of a group health plan shall submit to the ,comptroller ,general of the ,united ,states each of the first #d reports submitted to a plan sponsor under paragraph 7#a7 with respect to such coverage or plan1 and other such reports as requested1 in accordance with the privacy requirements under paragraph 7#b71 the disclosure and redisclosure standards under paragraph 7#c71 the standards specified pursuant to paragraph 7#e71 and such other information that the ,comptroller ,general determines necessary to carry out the study under section #b7;d7 of the ,better ,deals and ,lower ,prices ,act4 7#e7 ,standard format ,not later than #ah months after the date of enactment of this section1 the ,secretary shall specify through rulemaking standards for health insurance issuers and entities required to submit reports under paragraph 7#d7 to submit such reports in a standard format4 7c7 ,enforcement 7#a7 ,in general ,notwithstanding section #bgbc1 the ,secretary1 in consultation with the ,secretary of ,labor and the ,secretary of the ,treasury1 shall enforce this section4 7#b7 ,failure to provide timely information ,a health insurance issuer or an entity providing pharmacy benefits management services that violates subsection 7a7 or fails to provide information required under subsection 7b7 shall be subject to a civil monetary penalty in the amount of #aj1jjj for each day during which such violation continues or such information is not disclosed or reported4 7#c7 ,false information ,a health insurance issuer or entity providing pharmacy benefits management services that knowingly provides false information under this section shall be subject to a civil money penalty in an amount not to exceed #ajj1jjj for each item of false information4 ,such civil money penalty shall be in addition to other penalties as may be prescribed by law4 7#d7 ,procedure ,the provisions of section #aabh;,a of the ,social ,security ,act1 other than subsection 7a7 and 7b7 and the first sentence of subsection 7c77#a7 of such section shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under section #aabh;,a of the ,social ,security ,act4 7#e7 ,waivers ,the ,secretary may waive penalties under paragraph 7#b71 or extend the period of time for compliance with a requirement of this section1 for an entity in violation of this section that has made a good-faith effort to comply with this section4 7d7 ,rule of construction ,nothing in this section shall be construed to permit a health insurance issuer1 group health plan1 or other entity to restrict disclosure to1 or otherwise limit the access of1 the ,secretary of ,health and ,human ,services to a report described in subsection 7b77#a7 or information related to compliance with subsection 7a7 or 7b7 by such issuer1 plan1 or other entity subject to such subsections4 7e7 ,definition ,in this section1 the term wholesale acquisition cost has the meaning given such term in section #ahdg;,a7c77#f77;,b7 of the ,social ,security ,act4 2 and 7#b7 in section #bgbc 7#db ,u4,s4,c4 #cjj;gg-#bb7-- 7,a7 in subsection 7a7-- 7i7 in paragraph 7#a71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d2 and 7ii7 in paragraph 7#b71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d2 and 7,b7 in subsection 7b7-- 7i7 in paragraph 7#a71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d2 7ii7 in paragraph 7#b77;,a71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d2 and 7iii7 in paragraph 7#b77;,c77ii71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d4 7c7 ,,erisa 7#a7 ,in general ,subtitle ,b of title ,i of the ,employee ,retirement ,income ,security ,act of #aigd 7#bi ,u4,s4,c4 #ajba et seq47 is amended-- 7,a7 in subpart ,b of part #g 7#bi ,u4,s4,c4 #aahe et seq471 by adding at the end the following3 #gbf4 ,oversight of pharmacy benefits manager services 7a7 ,in general ,for plan years beginning on or after the date that is #c years after the date of enactment of this section1 a group health plan or health insurance issuer offering group health insurance coverage1 or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan or issuer1 shall not enter into a contract with a drug manufacturer1 distributor1 wholesaler1 subcontractor1 rebate aggregator1 or any associated third party that limits the disclosure of information to plan sponsors in such a manner that prevents the plan or issuer1 or an entity or subsidiary providing pharmacy benefits management services on behalf of a plan or issuer1 from making the report described in subsection 7b74 7b7 ,annual report 7#a7 ,in general ,with respect to plan years beginning on or after the date that is #c years after the date of enactment of this section1 for each such plan year1 a group health plan or health insurance issuer offering group health insurance coverage1 or an entity providing pharmacy benefits management services on behalf of such a plan or an issuer1 shall submit to the plan sponsor 7as defined in section #c7af77;,b77 of such plan or coverage a report in a machine-readable format4 ,each such report shall include1 with respect to such plan or coverage provided for such plan year-- 7,a7 to the extent feasible1 information collected from drug manufacturers 7or an entity administering copay assistance on behalf of such manufacturers7 by such plan or issuer on the total amount of copayment assistance dollars paid1 or copayment cards applied1 that were funded by the drug manufacturer with respect to the participants1 beneficiaries1 and enrollees in such plan or coverage2 7,b7 a list of each drug covered by such plan or coverage that was dispensed during the plan year1 including1 with respect to each such drug during such plan year-- 7i7 the brand name1 chemical entity1 and ,national ,drug ,code2 7ii7 the number of participants1 beneficiaries1 and enrollees for whom the drug was dispensed during the plan year1 the total number of prescription claims for the drug 7including original prescriptions and refills71 and the total number of dosage units of the drug dispensed across the plan year1 disaggregated by dispensing channel 7such as retail1 mail order1 or specialty pharmacy72 7iii7 the wholesale acquisition cost1 listed as cost per days supply and cost per pill1 or in the case of a drug in another form1 per dosage unit2 7iv7 the total out-of-pocket spending by participants1 beneficiaries1 and enrollees on such drug1 including participant1 beneficiary1 and enrollee spending through copayments1 coinsurance1 and deductibles2 7v7 for any drug for which gross spending of the group health plan or health insurance coverage exceeded #aj1jjj during the plan year-- 7,i7 a list of all other drugs in the same therapeutic category or class1 including brand name drugs and biological products and generic drugs or biosimilar biological products that are in the same therapeutic category or class as such drug2 and 7,,ii7 the rationale for the formulary placement of such drug in that therapeutic category or class1 if applicable2 7vi7 the amount received1 or expected to be received1 from drug manufacturers in rebates1 fees1 alternative discounts1 or other remuneration for claims incurred for such drug during the plan year2 7vii7 the total net spending1 after deducting rebates1 price concessions1 alternative discounts or other remuneration from drug manufacturers1 by the health plan or health insurance coverage on such drug2 and 7viii7 the net price per course of treatment or single fill1 such as a #cj-;day supply or #ij-;day supply1 incurred by the health plan or health insurance coverage and its participants1 beneficiaries1 and enrollees1 after manufacturer rebates1 fees1 and other remuneration for such drug dispensed during the plan year2 7,c7 a list of each therapeutic category or class of drugs that were dispensed under the health plan or health insurance coverage during the plan year1 and1 with respect to each such therapeutic category or class of drugs1 during the plan year-- 7i7 total gross spending by the plan or coverage1 before manufacturer rebates1 fees1 or other manufacturer remuneration2 7ii7 the number of participants1 beneficiaries1 and enrollees who were dispensed a drug covered by such plan or coverage in that category or class1 broken down by each such drug 7identified by ,national ,drug ,code72 7iii7 if applicable to that category or class1 a description of the formulary tiers and utilization management 7such as prior authorization or step therapy7 employed for drugs in that category or class2 and 7iv7 the total out-of-pocket spending by participants1 beneficiaries1 and enrollees1 including participant1 beneficiary1 and enrollee spending through copayments1 coinsurance1 and deductibles2 7,d7 total gross spending on prescription drugs by the plan or coverage during the plan year1 before rebates and other manufacturer fees or remuneration2 7,e7 total amount received1 or expected to be received1 by the health plan or health insurance coverage in drug manufacturer rebates1 fees1 alternative discounts1 and all other remuneration received from the manufacturer or any third party1 other than the plan sponsor1 related to utilization of drug or drug spending under that health plan or health insurance coverage during the plan year2 7,f7 the total net spending on prescription drugs by the health plan or health insurance coverage during the plan year2 and 7,g7 amounts paid directly or indirectly in rebates1 fees1 or any other type of remuneration to brokers1 consultants1 advisors1 or any other individual or firm for the referral of the group health plan's or health insurance issuer's business to the pharmacy benefits manager4 7#b7 ,privacy requirements ,health insurance issuers offering group health insurance coverage and entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph 7#a7 in a manner consistent with the privacy1 security1 and breach notification regulations promulgated under section #bfd7;c7 of the ,health ,insurance ,portability and ,accountability ,act of #aiif1 and shall restrict the use and disclosure of such information according to such privacy regulations4 7#c7 ,disclosure and redisclosure 7,a7 ,limitation to business associates ,a group health plan receiving a report under paragraph 7#a7 may disclose such information only to business associates of such plan as defined in section #afj4ajc of title #de1 ,code of ,federal ,regulations 7or successor regulations74 7,b7 ,clarification regarding public disclosure of information ,nothing in this section prevents a health insurance issuer offering group health insurance coverage or an entity providing pharmacy benefits management services on behalf of a group health plan from placing reasonable restrictions on the public disclosure of the information contained in a report described in paragraph 7#a71 except that such issuer or entity may not restrict disclosure of such report to the ,department of ,health and ,human ,services1 the ,department of ,labor1 the ,department of the ,treasury1 the ,comptroller ,general of the ,united ,states1 or applicable ,state agencies4 7,c7 ,limited form of report ,the ,secretary shall define through rulemaking a limited form of the report under paragraph 7#a7 required of plan sponsors who are drug manufacturers1 drug wholesalers1 or other direct participants in the drug supply chain1 in order to prevent anti-competitive behavior4 7#d7 ,report to ,,gao ,a group health plan or health insurance issuer offering group health insurance coverage1 or an entity providing pharmacy benefits management services on behalf of a group health plan shall submit to the ,comptroller ,general of the ,united ,states each of the first #d reports submitted to a plan sponsor under paragraph 7#a7 with respect to such coverage or plan1 and other such reports as requested1 in accordance with the privacy requirements under paragraph 7#b71 the disclosure and redisclosure standards under paragraph 7#c71 the standards specified pursuant to paragraph 7#e71 and such other information that the ,comptroller ,general determines necessary to carry out the study under section #b7;d7 of the ,better ,deals and ,lower ,prices ,act4 7#e7 ,standard format ,not later than #ah months after the date of enactment of this section1 the ,secretary shall specify through rulemaking standards for health insurance issuers and entities required to submit reports under paragraph 7#d7 to submit such reports in a standard format4 7c7 ,enforcement 7#a7 ,in general ,notwithstanding section #ejb1 the ,secretary1 in consultation with the ,secretary of ,health and ,human ,services and the ,secretary of the ,treasury1 shall enforce this section4 7#b7 ,failure to provide timely information ,a health insurance issuer or an entity providing pharmacy benefits management services that violates subsection 7a7 or fails to provide information required under subsection 7b7 shall be subject to a civil monetary penalty in the amount of #aj1jjj for each day during which such violation continues or such information is not disclosed or reported4 7#c7 ,false information ,a health insurance issuer or entity providing pharmacy benefits management services that knowingly provides false information under this section shall be subject to a civil money penalty in an amount not to exceed #ajj1jjj for each item of false information4 ,such civil money penalty shall be in addition to other penalties as may be prescribed by law4 7#d7 ,procedure ,the provisions of section #aabh;,a of the ,social ,security ,act1 other than subsection 7a7 and 7b7 and the first sentence of subsection 7c77#a7 of such section shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under section #aabh;,a of the ,social ,security ,act4 7#e7 ,waivers ,the ,secretary may waive penalties under paragraph 7#b71 or extend the period of time for compliance with a requirement of this section1 for an entity in violation of this section that has made a good-faith effort to comply with this section4 7d7 ,rule of construction ,nothing in this section shall be construed to permit a health insurance issuer1 group health plan1 or other entity to restrict disclosure to1 or otherwise limit the access of1 the ,secretary of ,labor to a report described in subsection 7b77#a7 or information related to compliance with subsection 7a7 or 7b7 by such issuer1 plan1 or other entity subject to such subsections4 7e7 ,definition ,in this section1 the term wholesale acquisition cost has the meaning given such term in section #ahdg;,a7c77#f77;,b7 of the ,social ,security ,act4 2 and 7,b7 in section #ejb 7#bi ,u4,s4,c4 #aacb7-- 7i7 in subsection 7a7-- 7,i7 in paragraph 7#f71 by striking or 7#i7 and inserting 7#i71 or 7#ac72 7,,ii7 in paragraph 7#aj71 by striking at the end or2 7,,iii7 in paragraph 7#aa71 at the end by striking the period and inserting 2 or2 and 7,,iv7 by adding at the end the following new paragraph3 7#ab7 by the ,secretary1 in consultation with the ,secretary of ,health and ,human ,services1 and the ,secretary of the ,treasury1 to enforce section #gbf4 2 7ii7 in subsection 7b77#c71 by inserting and subsections 7a77#ab7 and 7c77#ac7 before 1 the ,secretary is not2 and 7iii7 in subsection 7c71 by adding at the end the following new paragraph3 7#ac7 ,secretarial enforcement authority relating to oversight of pharmacy benefits manager services 7,a7 ,failure to provide timely information ,the ,secretary1 in consultation with the ,secretary of ,health and ,human ,services and the ,secretary of the ,treasury1 may impose a penalty against any health insurance issuer or entity providing pharmacy benefits management services that violates section #gbf7;a7 or fails to provide information required under section #gbf7;b7 in the amount of #aj1jjj for each day during which such violation continues or such information is not disclosed or reported4 7,b7 ,false information ,the ,secretary1 in consultation with the ,secretary of ,health and ,human ,services and the ,secretary of the ,treasury1 may impose a penalty against a health insurance issuer or entity providing pharmacy benefits management services that knowingly provides false information under section #gbf in an amount not to exceed #ajj1jjj for each item of false information4 ,such penalty shall be in addition to other penalties as may be prescribed by law4 7,c7 ,waivers ,the ,secretary may waive penalties under subparagraph 7,a71 or extend the period of time for compliance with a requirement of section #gbf1 for an entity in violation of such section that has made a good-faith effort to comply with such section4 4 7#b7 ,clerical amendment ,the table of contents in section #a of the ,employee ,retirement ,income ,security ,act of #aigd 7#bi ,u4,s4,c4 #ajja et seq47 is amended by inserting after the item relating to section #gbe the following new item3 ,sec4 #gbf4 ,oversight of pharmacy benefits manager services4 4 7d7 ,,gao study 7#a7 ,in general ,not later than #c years after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to ,congress a report on-- 7,a7 pharmacy networks of group health plans1 health insurance issuers1 and entities providing pharmacy benefits management services under such group health plan or group or individual health insurance coverage1 including networks that have pharmacies that are under common ownership 7in whole or part7 with group health plans1 health insurance issuers1 or entities providing pharmacy benefits management services or pharmacy benefits administrative services under group health plan or group or individual health insurance coverage2 7,b7 as it relates to pharmacy networks that include pharmacies under common ownership described in subparagraph 7,a7-- 7i7 whether such networks are designed to encourage enrollees of a plan or coverage to use such pharmacies over other network pharmacies for specific services or drugs1 and if so1 the reasons the networks give for encouraging use of such pharmacies2 and 7ii7 whether such pharmacies are used by enrollees disproportionately more in the aggregate or for specific services or drugs compared to other network pharmacies2 7,c7 whether group health plans and health insurance issuers offering group or individual health insurance coverage have options to elect different network pricing arrangements in the marketplace with entities that provide pharmacy benefits management services1 the prevalence of electing such different network pricing arrangements2 7,d7 pharmacy network design parameters that encourage enrollees in the plan or coverage to fill prescriptions at mail order1 specialty1 or retail pharmacies that are wholly or partially-owned by that issuer or entity2 and 7,e7 the degree to which mail order1 specialty1 or retail pharmacies that dispense prescription drugs to an enrollee in a group health plan or health insurance coverage that are under common ownership 7in whole or part7 with group health plans1 health insurance issuers1 or entities providing pharmacy benefits management services or pharmacy benefits administrative services under group health plan or group or individual health insurance coverage receive reimbursement that is greater than the median price charged to the group health plan or health insurance issuer when the same drug is dispensed to enrollees in the plan or coverage by other pharmacies included in the pharmacy network of that plan1 issuer1 or entity that are not wholly or partially owned by the health insurance issuer or entity providing pharmacy benefits management services4 7#b7 ,requirement ,the ,comptroller ,general of the ,united ,states shall ensure that the report under paragraph 7#a7 does not contain information that would allow a reader to identify a specific plan or entity providing pharmacy benefits management services or otherwise contain commercial or financial information that is privileged or confidential4 7#c7 ,definitions ,in this subsection1 the terms group health plan1 health insurance coverage1 and health insurance issuer have the meanings given such terms in section #bgia of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ia74